IgA Nephropathy Got Two New Drugs in Ten Days. Here's What Trutakna and Fabhalta Actually Do Differently.

IgA nephropathy is a rare kidney disease that affects roughly 130,000 to 150,000 Americans. It is the most common primary glomerular disease worldwide. About 40 percent of patients progress to end-stage kidney disease within 20 years without effective treatment.

Until this month, the main drugs doctors used were older medicines that lower blood pressure and reduce protein in the urine (ACE inhibitors, ARBs, SGLT2 inhibitors like Farxiga, and the newer endothelin blockers Filspari and Vanrafia). Two brand-new drugs joined the list in the last ten days.

On July 7, 2026, the FDA approved Vera Therapeutics' Trutakna (atacicept-vymj). Trutakna is a peptide-and-antibody fusion protein that blocks two signals your immune system uses to make antibodies. In the ORIGIN Phase 3 trial, patients on Trutakna plus standard care had 45.7 percent less protein leaking into their urine at 36 weeks, compared with 6.8 percent for standard care alone.

On July 17, 2026, the FDA gave full approval to Novartis's Fabhalta (iptacopan). Fabhalta is a small molecule that blocks a completely different part of the immune system called complement Factor B. In the APPLAUSE-IgAN Phase 3 trial, Fabhalta slowed kidney function decline by 48 percent compared with placebo.

Both drugs sit on top of standard care. Neither replaces it. They work through different biology, they measure success against different endpoints, and they will cost patients different amounts. This piece walks through what each drug does, what the trials actually showed, and what to think about if either is an option for you.

IgA nephropathy (often shortened to IgAN, sometimes called Berger's disease) is a kidney disease where the body's immune system makes a specific type of antibody, called IgA, that clumps together and gets stuck in the filtering units of the kidneys (the glomeruli).

Over years, those IgA clumps trigger inflammation. The inflammation damages the filters. The damaged filters leak protein into the urine. As more filters are damaged, the kidney becomes less able to clean the blood. Eventually, some patients need dialysis or a kidney transplant.

Most people find out they have IgAN in their 20s or 30s, though it can appear at any age. The classic sign is dark, cola-colored urine after a cold or a sore throat. Other patients get diagnosed after a routine urine test shows protein or blood. The disease progresses slowly for some people and quickly for others.

The rate of progression to end-stage kidney disease varies. About 30 to 40 percent of adult IgAN patients progress to needing dialysis or a transplant within 20 to 25 years of diagnosis. Patients with higher urine protein levels, higher blood pressure, and reduced kidney function at diagnosis have faster progression.

The old standard of care aims to slow that progression: control blood pressure with ACE inhibitors or ARBs, add an SGLT2 inhibitor (Farxiga/dapagliflozin) for kidney protection, sometimes add an endothelin receptor blocker (Filspari/sparsentan or Vanrafia/atrasentan for proteinuria reduction). Corticosteroids get used in a subset of patients but carry side-effect burdens. Until this month, no drug targeted the immune-system source of the problem for a broad IgAN population.

Trutakna (atacicept-vymj), approved July 7, 2026

Developed by Vera Therapeutics (NASDAQ: VERA). Marketed as Trutakna. FDA granted accelerated approval based on the Phase 3 ORIGIN trial.

What it is: a recombinant fusion protein. Half of the molecule is the outer part of a receptor called TACI (transmembrane activator and CAML interactor). The other half is the Fc portion of a human IgG1 antibody. Attached together, the fusion protein grabs and neutralizes two signaling molecules called BAFF and APRIL.

How it is given: weekly subcutaneous (under-the-skin) injection.

Mechanism target: BAFF and APRIL, which are cytokines that keep B cells alive and drive antibody production. Blocking them reduces the abnormal IgA production that starts the whole disease process.

Fabhalta (iptacopan), full FDA approval July 17, 2026

Developed by Novartis (SIX: NOVN). Marketed as Fabhalta. First FDA accelerated approval was August 2024 for proteinuria reduction. Traditional approval on July 17, 2026 based on the Phase 3 APPLAUSE-IgAN trial and its kidney-function outcome.

What it is: a small molecule (not a peptide or antibody). It blocks an enzyme called complement Factor B.

How it is given: oral capsule taken twice daily.

Mechanism target: the alternative complement pathway. Complement is a system of blood proteins that helps antibodies attack invaders. In IgAN, activation of complement worsens kidney damage. Blocking Factor B shuts down the pathway locally in the glomerulus.

Both drugs sit on top of the standard-of-care backbone. Neither replaces ACE inhibitors, ARBs, or SGLT2 inhibitors. The trials tested each drug added to that backbone versus the backbone alone.

IgA nephropathy starts with the wrong kind of IgA antibodies. Your body makes IgA normally to defend the lining of your gut, lungs, and other surfaces. In IgAN patients, some of the IgA is missing a sugar molecule at a specific location (a change called galactose deficiency). Those abnormal IgA antibodies clump together, form immune complexes, and get trapped in the kidney filters.

What keeps the B cells (the immune cells that make those bad IgA antibodies) alive and productive? Two signaling molecules called BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Both are released by other immune cells and both bind to receptors on B cells and plasma cells. Turn them off, and the B cells stop making so much antibody.

Trutakna is engineered to grab both BAFF and APRIL out of the bloodstream before they can reach the B cells. The molecule combines the outer part of TACI (a receptor that naturally binds both BAFF and APRIL) with the Fc tail of a human antibody. The TACI half does the grabbing. The Fc half gives the drug a longer half-life and stability in the body.

The practical effect: less BAFF and APRIL signaling, fewer plasma cells making the abnormal IgA, less immune-complex deposition in the kidney, less inflammation, less kidney damage over time.

The design belongs to the peptide-and-Fc fusion protein category (the same modality as Vera Trutakna's competitors in adjacent B-cell diseases, like belimumab in lupus). It is a large molecule that has to be injected, not swallowed. The current dosing is once weekly. Vera plans to launch commercially in Q3 2026.

The complement system is a set of blood proteins that helps antibodies clear pathogens. It works through a cascade: one protein activates the next, which activates the next, and so on, ending with the destruction of the target.

Complement has three activation pathways: classical, lectin, and alternative. In IgA nephropathy, the alternative pathway gets over-activated inside the kidney. Immune complexes deposited in the glomerulus (the kidney filter) trigger complement, which produces inflammatory signals that damage the filter.

Complement Factor B is a critical enzyme in the alternative pathway. Without Factor B, the alternative pathway cannot amplify itself. That amplification step is what turns a small trigger into significant tissue damage.

Fabhalta (iptacopan) is a small molecule that binds directly to Factor B and blocks it. Because it is a small molecule, it can be taken as a capsule twice daily. The drug reaches the kidney filter in high enough concentration to shut down local complement activation, which reduces inflammation and slows the loss of filtering function.

Novartis originally received FDA accelerated approval for Fabhalta in August 2024 based on proteinuria reduction in interim APPLAUSE-IgAN data. The July 17, 2026 traditional approval is based on the completed Phase 3 study and its kidney-function endpoint, which is a stronger evidence bar. Fabhalta is also FDA-approved for two other complement-mediated diseases: paroxysmal nocturnal hemoglobinuria (2023) and C3 glomerulopathy (2025), which gives Novartis a broader commercial footprint.

The two Phase 3 trials measured different things. That matters for how you compare the drugs.

Trutakna in ORIGIN (measured protein in the urine)

ORIGIN was a Phase 3 randomized placebo-controlled trial in adults with primary IgAN at risk of progression. The primary endpoint was change in urine protein-to-creatinine ratio (UPCR) at 36 weeks. UPCR measures how much protein is leaking through the damaged kidney filter into the urine.

Results: Trutakna plus standard of care produced a 45.7 percent reduction in UPCR at 36 weeks. Standard of care alone produced a 6.8 percent reduction. The gap was about 39 percentage points, which is a large effect size for this endpoint.

What this tells you: less protein leaks through the damaged filter. That is a useful biomarker because protein leakage correlates with kidney damage. It is not the same as showing the kidney function itself is improved.

Fabhalta in APPLAUSE-IgAN (measured actual kidney function)

APPLAUSE-IgAN also enrolled adults with primary IgAN, but the endpoint was different. Fabhalta was measured on the estimated glomerular filtration rate (eGFR) slope, which is the rate at which kidney function declines over time. eGFR is calculated from a blood test (creatinine) and captures how well the kidneys are actually filtering.

Results: patients on Fabhalta had 3.02 mL/min/1.73 m² per year better eGFR slope than placebo. That is a 48 percent slower decline in kidney function.

What this tells you: patients preserved kidney function for longer. That is closer to the outcome patients care about (staying off dialysis).

Endpoint difference summary

UPCR reduction (Trutakna's endpoint) is a downstream biomarker: less protein leakage. It happens quickly and reads out at 36 weeks.

eGFR slope (Fabhalta's endpoint) is closer to the hard clinical outcome: preserved kidney function over years. It reads out slowly and is a stronger evidence bar for regulatory approval.

FDA accepts both endpoints for accelerated approval on the biomarker (UPCR) and traditional approval on the harder outcome (eGFR slope). Both drugs are in the accelerated-to-traditional pipeline; Fabhalta reached the traditional stage first because it had a longer follow-up period.

The safety profiles differ because the mechanisms differ.

Trutakna (BAFF/APRIL blocker)

Main concern: infection risk. BAFF and APRIL are important for antibody production. Blocking them reduces the immune system's ability to make antibodies against pathogens. Patients on Trutakna in the ORIGIN trial had a higher rate of infections than patients on standard care. Serious infections were uncommon but did occur.

Other labeled warnings: potential drop in immunoglobulin levels over time (which is what you'd expect from the mechanism), injection-site reactions from the weekly subcutaneous administration.

Continued FDA approval is contingent on verification of clinical benefit in confirmatory Phase 3 studies. In practice this means Vera has to keep gathering longer-term data to keep the approval.

Fabhalta (complement Factor B blocker)

Main concern: infections with encapsulated bacteria. Complement is critical for defense against bacteria like Neisseria meningitidis (which causes meningococcal disease), Streptococcus pneumoniae (which causes pneumonia), and Haemophilus influenzae. Blocking complement raises the risk of infection with those bacteria.

The FDA label requires patients to be vaccinated against meningococcus, pneumococcus, and Hib at least two weeks before starting Fabhalta. Patients also carry a card describing the risk and get a boxed warning about meningococcal infection.

Other Fabhalta considerations: potential effects on liver enzymes; use with caution in patients with active infections.

For either drug, the discussion with a nephrologist should cover baseline immune function, vaccination status, and any history of frequent infections.

Trutakna list price and detailed insurance coverage picture were still forming at approval. Vera Therapeutics guided to a Q3 2026 commercial launch. Comparable BAFF/APRIL-adjacent biologics for kidney and autoimmune diseases have list prices in the tens of thousands of dollars per year for weekly-injection therapy. Patient assistance programs from Vera are expected. Because Trutakna is administered as a subcutaneous injection, insurance coverage typically runs through medical benefits (buy-and-bill) rather than pharmacy benefits.

Fabhalta was already launched in the US when the IgAN traditional approval landed on July 17, 2026, because Novartis had earlier accelerated approval (proteinuria) and separate approvals in paroxysmal nocturnal hemoglobinuria (2023) and C3 glomerulopathy (2025). The list price is approximately $225,000 per year based on Novartis's earlier disclosures. Insurance coverage typically runs through pharmacy benefits (patient picks it up from a specialty pharmacy). Novartis maintains a patient assistance program.

Both drugs are expensive. Both are typically covered by commercial insurance for on-label use with prior authorization. Medicare Part D coverage varies by plan; some patients face significant coinsurance. Patients considering either drug should ask about:

• Whether their insurance covers the drug on formulary
• Prior authorization requirements
• Copay assistance from the manufacturer
• Independent nonprofit foundations that help with copays for rare kidney diseases

Cost-effectiveness comparisons between the two drugs have not been formally published as of approval. Real-world price negotiations between Novartis and pharmacy benefit managers may shift the effective net cost significantly.

Neither trial directly compared Trutakna against Fabhalta. That head-to-head study does not exist. What follows is a framework for a conversation with a nephrologist, not a personal recommendation.

Reasons Trutakna might be considered first

• The patient has notable proteinuria that has not responded well to standard care plus SGLT2 inhibitor and endothelin blocker
• The patient tolerates injections and prefers weekly dosing to twice-daily pills
• The patient does not have a history of frequent infections
• The prescribing nephrologist wants to target the upstream immune-cell driver of IgA production

Reasons Fabhalta might be considered first

• The patient has documented eGFR decline that has been the main concern (beyond proteinuria alone)
• The patient prefers oral dosing to injections
• The patient can be vaccinated fully against meningococcus, pneumococcus, and Hib before starting
• The prescribing nephrologist wants to target the downstream complement inflammation

Reasons to hold both and stay on standard care

• The patient is well-controlled on ACE inhibitor plus SGLT2 inhibitor plus endothelin blocker
• Kidney function is stable and proteinuria is low
• Insurance coverage or cost is a barrier that is not surmountable
• The patient wants to see a longer track record on either new drug

One more thing worth knowing: the IgAN field is moving fast. Additional drugs are in Phase 3 (including sibeprenlimab, another anti-APRIL antibody from Otsuka/Visterra with FDA accelerated approval in April 2026; and additional complement pathway drugs from other sponsors). If neither Trutakna nor Fabhalta feels right in 2026, additional options are likely to arrive in 2027 and 2028.

Whether either drug prevents kidney failure long term. Both drugs slow the disease at surrogate endpoints (proteinuria for Trutakna, eGFR slope for Fabhalta). Neither has shown a reduction in the hard outcome of dialysis or transplant yet. Trutakna's confirmatory Phase 3 will address this over the next several years. Fabhalta has longer follow-up but the actual reduction in dialysis or transplant rates has not been reported.

How the drugs perform against each other. No head-to-head trial exists. The trials used different endpoints, so cross-trial comparison is limited. Real-world evidence and network meta-analyses may fill part of the gap over 2027-2028.

Which patients benefit most from each mechanism. IgAN is heterogeneous. Some patients have very high IgA production (where Trutakna's mechanism should help most). Some have very active complement activation (where Fabhalta's mechanism should help most). Biomarkers that predict which drug will work better for which patient are not yet validated in clinical practice.

Long-term infection risk. Both drugs suppress parts of the immune system. Post-marketing surveillance and long-term extension studies will characterize infection risk over years, well beyond the 36-week or 2-year windows.

Cost effectiveness under real-world pricing. The published list prices are starting points. The net prices after rebates and pharmacy benefit manager negotiation may look different. Payers may require step therapy (try the older drugs first) before covering either.

What sequencing makes sense. If a patient starts Trutakna and does not respond, can they switch to Fabhalta? If they progress on Fabhalta, is Trutakna a next step? Add-on data (using both drugs together) does not exist. Sequencing guidance will develop as clinical experience accumulates.

IgA nephropathy went from a disease with only supportive care (blood pressure, SGLT2 inhibitor, blocking angiotensin) to a disease with mechanism-targeted therapy in a very short period. April 2025 brought Vanrafia (atrasentan) for proteinuria. February 2026 brought fresh KDIGO clinical practice guidelines that formalized the SGLT2-plus-endothelin blocker foundation. July 7 brought Trutakna. July 17 brought the Fabhalta traditional approval. Sibeprenlimab and other programs are close behind.

For a patient diagnosed with IgAN today, the practical steps are the same as they have been:

1. Get an accurate diagnosis, including a kidney biopsy if not already done
2. Optimize blood pressure control with an ACE inhibitor or ARB at the highest tolerated dose
3. Start an SGLT2 inhibitor (Farxiga or Jardiance) unless contraindicated
4. Consider an endothelin receptor blocker (Filspari or Vanrafia) if proteinuria remains high
5. Talk to the nephrologist about whether Trutakna or Fabhalta is a good next step based on your specific disease pattern (level of proteinuria, rate of eGFR decline, prior treatment response)

The two new July 2026 drugs are not silver bullets. They are substantial additions to a toolkit that has expanded fast. Every patient's disease pattern is different, and treatment decisions belong in the specialist's office. This piece exists to help you go into that office with better questions.